FTC Continues Crackdown On Deceptive CBD Claims

FK
Frankfurt Kurnit Klein & Selz

Contributor

Frankfurt Kurnit provides high quality legal services to clients in many industries and disciplines worldwide. With leading practices in entertainment, advertising, IP, technology, litigation, corporate, estate planning, charitable organizations, professional responsibility and other areas — Frankfurt Kurnit helps clients face challenging legal issues and meet their goals with efficient solutions.
The Federal Trade Commission announced that it reached a settlement with Kushly Industries, resolving allegations that the company made deceptive claims that its CBD products...
United States Media, Telecoms, IT, Entertainment
To print this article, all you need is to be registered or login on Mondaq.com.

The Federal Trade Commission  announced that it reached a settlement with Kushly Industries, resolving allegations that the company made deceptive claims that its CBD products could effectively treat or cure a variety of health conditions.  

This is the seventh case that the FTC has brought against marketers of CBD products.  In the FTC's "Business Blog," Senior Attorney Lesley Fair  wrote that this case "demonstrates the FTC's ongoing commitment to challenging misrepresentations that a product is effective for preventing or treating serious conditions." 

The FTC alleged that Kushly made false or unsubstantiated claims that the company's gummies, ointments, and other products with CBD could treat ailments such as acne, psoriasis, cancer, and multiple sclerosis.  The FTC pointed to claims such as:

  • "It can treat neurological disorders such as . . . multiple sclerosis";
  • "CBD has the capacity to lower blood pressure"; and
  • "Being an anti-inflammatory substance, CBD is being used to treat acne, psoriasis, and other skin irritations." 

As part of the announcement of the  settlement, Daniel Kaufman, Acting Director of the FTC's Bureau of Consumer Protection, said, “This is the seventh case we've brought against CBD sellers who should know better than to make unsupported health claims for their products.  There may be some benefits of CBD, but there's no proof that it can treat the serious health conditions in Kushly's advertising, such as Parkinson's, multiple sclerosis, or cancer.”

In addition to prohibiting the company from making false health claims in the future, the settlement also requires Kushly to pay more than $30,000 of restitution to consumers.  

www.fkks.com

This alert provides general coverage of its subject area. We provide it with the understanding that Frankfurt Kurnit Klein & Selz is not engaged herein in rendering legal advice, and shall not be liable for any damages resulting from any error, inaccuracy, or omission. Our attorneys practice law only in jurisdictions in which they are properly authorized to do so. We do not seek to represent clients in other jurisdictions.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More